Technical Analysis for VSTM - Verastem, Inc.

Grade Last Price % Change Price Change
grade D 3.24 -6.90% -0.24
VSTM closed down 6.9 percent on Friday, March 22, 2019, on 84 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Flat Down
See historical VSTM trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 50 DMA Bearish 0.00%
Mar 22 Stochastic Sell Signal Bearish 0.00%
Mar 22 Upper Bollinger Band Walk Strength 0.00%
Mar 22 Overbought Stochastic Strength 0.00%
Mar 21 Calm After Storm Range Contraction -6.90%
Mar 21 Upper Bollinger Band Walk Strength -6.90%
Mar 21 Weak + Overbought Other -6.90%
Mar 21 Outside Day Range Expansion -6.90%
Mar 21 Overbought Stochastic Strength -6.90%
Mar 21 Upper Bollinger Band Touch Strength -6.90%

Older signals for VSTM ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs) with companion diagnostics. Its programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. The company's lead FAK inhibitor, VS-6063, is in Phase I/Ib testing in ovarian cancer, as well as developing for the treatment of mesothelioma and breast cancer. It is also developing FAK inhibitor VS-4718 and PI3K/mTOR inhibitor VS-5584 in patients with advanced cancers. The company's product candidates target CSCs that have been implicated in aggressive cancers, metastasis, and chemotherapeutic resistance. Verastem, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Medicine Biopharmaceutical Cancer Oncology Stem Cells Breast Cancer Ovarian Cancer Cancer Research Signal Transduction Cancer Stem Cell Metastasis Cancer Stem Cells Mesothelioma Mtor
Is VSTM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 10.35
52 Week Low 2.61
Average Volume 2,885,746
200-Day Moving Average 5.7553
50-Day Moving Average 3.241
20-Day Moving Average 3.157
10-Day Moving Average 3.293
Average True Range 0.2674
ADX 12.34
+DI 21.9176
-DI 20.5548
Chandelier Exit (Long, 3 ATRs ) 2.8578
Chandelier Exit (Short, 3 ATRs ) 3.4122
Upper Bollinger Band 3.5835
Lower Bollinger Band 2.7305
Percent B (%b) 0.6
BandWidth 27.019322
MACD Line 0.042
MACD Signal Line -0.0086
MACD Histogram 0.0507
Fundamentals Value
Market Cap 119.85 Million
Num Shares 37 Million
EPS -1.24
Price-to-Earnings (P/E) Ratio -2.61
Price-to-Sales 0.00
Price-to-Book 2.72
PEG Ratio -1.48
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.75
Resistance 3 (R3) 3.79 3.67 3.67
Resistance 2 (R2) 3.67 3.54 3.65 3.64
Resistance 1 (R1) 3.45 3.46 3.39 3.41 3.61
Pivot Point 3.33 3.33 3.30 3.31 3.33
Support 1 (S1) 3.11 3.20 3.05 3.07 2.87
Support 2 (S2) 2.99 3.12 2.97 2.84
Support 3 (S3) 2.77 2.99 2.82
Support 4 (S4) 2.73